TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study
Brief Summary: To date, there has been many methods suggested to reduce pancreatic fistula. But there are no evidence of superiority to the other methods. This study is a multicenter prospective randomized phase III study of use of Tachocomb or Polyethylene Glycolic Acid (PGA) to prevent of pancreatic fistula after distal pancreatectomy.


Options:
A: Arm Label: Pancreatic duct occlusion; Type: EXPERIMENTAL; Interventions: Procedure: Pancreatic duct occlusion with Neoprene | Arm Label: Pancreato-Jejunal anastomosi; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pancreato-Jejunal anastomosis | Intervention Type: PROCEDURE; Name: Pancreatic duct occlusion with Neoprene; Assigned to Arm(s): Pancreatic duct occlusion | Intervention Type: PROCEDURE; Name: Pancreato-Jejunal anastomosis; Assigned to Arm(s): Pancreato-Jejunal anastomosi
B: Arm Label: application of TachoSil®; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen/thrombin-coated collagen patch | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fibrinogen/thrombin-coated collagen patch; Assigned to Arm(s): application of TachoSil®
C: Arm Label: Tachocomb; Type: ACTIVE_COMPARATOR; Interventions: Device: Tachocomb | Arm Label: PGA; Type: ACTIVE_COMPARATOR; Interventions: Device: Polyglycolic acid (PGA) (Neoveil) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tachocomb; Assigned to Arm(s): Tachocomb | Intervention Type: DEVICE; Name: Polyglycolic acid (PGA) (Neoveil); Assigned to Arm(s): PGA
D: Arm Label: Patch and glue arm; Type: EXPERIMENTAL; Interventions: Procedure: Falciform patch and fibrin glue application | Arm Label: stapled /sutured pancreatic closure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard pancreatic closure | Intervention Type: PROCEDURE; Name: Falciform patch and fibrin glue application; Assigned to Arm(s): Patch and glue arm | Intervention Type: PROCEDURE; Name: standard pancreatic closure; Assigned to Arm(s): stapled /sutured pancreatic closure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preparing Older Veterans With Serious and Chronic Illness for Decision Making
Brief Summary: Millions of diverse Veterans live with severe and chronic illness for which they will face complex, ongoing decisions. Although the VHA has been at the forefront of patient-centered chronic care, interventions to prepare Veterans for complex decision-making over the course of chronic illness are lacking. This proposal addresses this gap by testing the efficacy of a novel preparation guide designed to prepare Veterans to communicate with their surrogates and to work with clinicians to make complex, ongoing decisions. The multi-media guide teaches communication and preparation skill behaviors (e.g., how to choose a surrogate and ask clinicians questions) in a culturally appropriate, easy-to-use format (targeted to a 5th grade reading level). This study aims to provide an impetus for changing the paradigm of advance care planning policies within the VA by moving beyond documentation of end-of-life wishes to the activation of Veterans to participate in ongoing communication of their values and goals - a process that is essential to fully realize patient-centered care.


Options:
A: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support
B: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Usual care; Type: OTHER; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
C: Arm Label: PREPARE; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE website | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advance directive | Intervention Type: BEHAVIORAL; Name: PREPARE website; Assigned to Arm(s): PREPARE | Intervention Type: BEHAVIORAL; Name: Advance directive; Assigned to Arm(s): CONTROL
D: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
D: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
B: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
B: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
D: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients
Brief Summary: This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.


Options:
A: Arm Label: EVR/TAC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: TAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): EVR/TAC | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): EVR/TAC, TAC | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR/TAC, TAC
B: Arm Label: Everolimus + reduced tacrolimus; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus (reduced tacrolimus), Drug: Everolimus (reduced tacrolimus), Drug: Corticosteroids | Arm Label: Tacrolimus elimination; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus (tacrolimus elimination), Drug: Everolimus (tacrolimus elimination), Drug: Corticosteroids | Arm Label: Tacrolimus control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus (tacrolimus control), Drug: Corticosteroids | Intervention Type: DRUG; Name: Tacrolimus (reduced tacrolimus); Assigned to Arm(s): Everolimus + reduced tacrolimus | Intervention Type: DRUG; Name: Tacrolimus (tacrolimus elimination); Assigned to Arm(s): Tacrolimus elimination | Intervention Type: DRUG; Name: Tacrolimus (tacrolimus control); Assigned to Arm(s): Tacrolimus control | Intervention Type: DRUG; Name: Everolimus (reduced tacrolimus); Assigned to Arm(s): Everolimus + reduced tacrolimus | Intervention Type: DRUG; Name: Everolimus (tacrolimus elimination); Assigned to Arm(s): Tacrolimus elimination | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Everolimus + reduced tacrolimus, Tacrolimus control, Tacrolimus elimination
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: ATG (Fresenius Biotech); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444)) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy over twelve months in subjects diagnosed with COPD. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.


Options:
A: Arm Label: GW642444M/lactose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: GW642444M/MgSt; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: Magnesium Stearate; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo
B: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: FF/VI | Arm Label: Existing Maintenance Therapy; Type: OTHER; Interventions: Other: Existing Maintenance Therapy | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): FF/VI | Intervention Type: OTHER; Name: Existing Maintenance Therapy; Assigned to Arm(s): Existing Maintenance Therapy
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW642444M; Type: EXPERIMENTAL; Interventions: Drug: GW642444M | Intervention Type: DRUG; Name: GW642444M; Assigned to Arm(s): GW642444M | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia
Brief Summary: The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine 60 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Amiloride; Type: EXPERIMENTAL; Interventions: Drug: Amiloride | Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Amiloride | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia
Brief Summary: The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.


Options:
A: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine 60 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial).
Brief Summary: This is a multicenter, double-blind, randomized trial to assess the efficacy and safety of colchicine for post-pericardiotomy syndrome prevention, post-operative effusions prevention, and post-operative atrial fibrillation prevention.


Options:
A: Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: High Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: High Dose Colchicine (4.8 mg total dose) | Arm Label: Low Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Low Dose Colchicine (1.8mg total dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Control | Intervention Type: DRUG; Name: High Dose Colchicine (4.8 mg total dose); Assigned to Arm(s): High Dose Colchicine | Intervention Type: DRUG; Name: Low Dose Colchicine (1.8mg total dose); Assigned to Arm(s): Low Dose Colchicine | Intervention Type: OTHER; Name: Placebo Control; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D